amsacrine has been researched along with Brain Neoplasms in 5 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to fabricate and investigate amsacrine containing polymeric rods for use in interstitial chemotherapy of malignant glioma." | 7.69 | Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. ( Almqvist, PM; Boëthius, J; Glantz, MJ; Wahlberg, LU, 1996) |
| "The purpose of this study was to fabricate and investigate amsacrine containing polymeric rods for use in interstitial chemotherapy of malignant glioma." | 3.69 | Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model. ( Almqvist, PM; Boëthius, J; Glantz, MJ; Wahlberg, LU, 1996) |
| "Dexrazoxane (ICRF-187) is a catalytic inhibitor of the nuclear enzyme DNA topoisomerase II (topo II)." | 1.30 | Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. ( Holm, B; Jensen, PB; Sehested, M, 1998) |
| "with either L1210 cells or Ehrlich ascites tumor cells." | 1.29 | ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. ( Holm, B; Jensen, PB; Sehested, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T | 1 |
| Zwelling, LA | 2 |
| An, T | 1 |
| McWatters, A | 1 |
| Herzog, CE | 1 |
| Mayes, J | 1 |
| Loughlin, SM | 1 |
| Kleinerman, ES | 1 |
| Holm, B | 2 |
| Jensen, PB | 2 |
| Sehested, M | 2 |
| Wahlberg, LU | 1 |
| Almqvist, PM | 1 |
| Glantz, MJ | 1 |
| Boëthius, J | 1 |
| Estey, E | 1 |
| Silberman, L | 1 |
| Doyle, S | 1 |
| Hittelman, W | 1 |
5 other studies available for amsacrine and Brain Neoplasms
| Article | Year |
|---|---|
Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
Topics: Amsacrine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 1996 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; B | 1996 |
Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model.
Topics: Amsacrine; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Division; Delayed-Actio | 1996 |
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neo | 1998 |
Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts.
Topics: Amsacrine; Brain Neoplasms; Cell Division; Chromatin; DNA; DNA Topoisomerases, Type II; Fibroblasts; | 1987 |